MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, APVO had $12,905K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$12,905K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Non-cash lease expense
    • Proceeds from exercise of common...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Operating lease liability
    • Accounts payable, accrued compen...

Cash Flow
2025-12-31
Net loss
-25,967
Stock-based compensation
96
Non-cash lease expense
1,089
Depreciation and amortization
240
Prepaid expenses and other current assets
-483
Accounts payable, accrued compensation, accrued expenses and other current liabilities, and short-term operating lease
-157
Operating lease liability
-1,376
Net cash used in operating activities
-25,592
Net cash from investing activities
0
Value of equity awards withheld for tax liability
0
Proceeds from exercise of common warrants, net of issuance costs
557
Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs
37,940
Net cash provided by financing activities
38,497
Increase (decrease) in cash and cash equivalents
12,905
Cash and cash equivalents at beginning of period
8,714
Cash and cash equivalents at end of period
21,619
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock,...$37,940K Proceeds from exercise ofcommon warrants, net of...$557K Net cash provided byfinancing activities$38,497K Increase (decrease) incash and cash...$12,905K Canceled cashflow$25,592K Non-cash lease expense$1,089K Prepaid expenses andother current assets-$483K Depreciation andamortization$240K Stock-based compensation$96K Net cash used inoperating activities-$25,592K Canceled cashflow$1,908K Net loss-$25,967K Operating lease liability-$1,376K Accounts payable,accrued compensation,...-$157K

Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Inc. (APVO)